There are currently 97 clinical trials in Lubbock, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including Texas Tech University Health Science Center, Covenant Children's Hospital, Joe Arrington Cancer Research and Treatment Center and UMC Cancer Center / UMC Health System. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Annatto-derived GG for Statin-associated Myopathy
NCT05312424
Recruiting
To evaluate the effects of 3-months annatto-derived geranylgeraniol (GG) supplementation on statin-associated skeletal muscle health.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/02/2024
Locations: Texas Tech University Health Sciences Center, Lubbock, Texas
Conditions: Myopathy; Primary
Register for Updates
Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction
NCT01526681
Recruiting
This study is a registry of general use of Avance Nerve Graft and is intended to evaluate the uses, response rates, and safety of Avance Nerve Graft in the real-life clinical setting. Optional addendums 1 and 2 included in the protocol are intended to establish comparative groups and focused subgroups within the registry.
Gender:
ALL
Ages:
All
Trial Updated:
07/25/2024
Locations: RANGER: Texas Tech University HSC, Lubbock, Texas
Conditions: Peripheral Nerve Injuries
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Covenant Medical Center-Lakeside, Lubbock, Texas
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
NCT03053193
Recruiting
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: Texas Tech UHSC - Southwest Cancer Center, Lubbock, Texas
Conditions: Breast Cancer
Register for Updates
Assessing the Impact of Botulinum Toxin Type A on Facial Wrinkles: A Comprehensive Clinical Investigation
NCT06385171
Recruiting
A study conducting to see how well a treatment called Botulinum Toxin Type A works for reducing facial wrinkles. The study will help us understand if this treatment is safe and effective for making wrinkles on the face less noticeable.
Gender:
ALL
Ages:
Between 20 years and 65 years
Trial Updated:
05/23/2024
Locations: Global Aesthetics LLC, Lubbock, Texas
Conditions: Wrinkle
Register for Updates
Connect® Myeloid Disease Registry
NCT01688011
Recruiting
The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification which may or may not be predictive of therapy and clinical outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Southwest Cancer Treatment & Research Center, Lubbock, Texas
Conditions: Myelodysplastic Syndromes, Primary Myelofibrosis, Leukemia, Myeloid, Acute
Register for Updates
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
NCT03418961
Recruiting
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: UMC Cancer Center / UMC Health System, Lubbock, Texas
Conditions: Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Register for Updates
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: GI Alliance - Lubbock Digestive Disease Associates - Lubbock, Lubbock, Texas
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates
Naltrexone for Prolonged Grief Disorder
NCT06140420
Recruiting
This is a study to see how effective oral naltrexone is as treatment for prolonged grief disorder (PGD). Participants will take their assigned medication for 8 weeks, with monthly visits to assess symptom severity, social connectedness, and adverse reactions.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
11/18/2023
Locations: Texas Tech Health Science Center, Lubbock, Texas
Conditions: Naltrexone HCl 50 MG Oral Tablet, Placebo
Register for Updates
The Effect of 4 Weeks of L-Citrulline Supplementation on Macro- and Microvascular Function in Type 2 Diabetes
NCT06016478
Recruiting
The purpose of this study is to examine the effect of 4 weeks of Citrulline supplementation on macro- and microvascular function during acute hyperglycemia in middle-aged and older adults with type 2 diabetes.
Gender:
ALL
Ages:
Between 40 years and 75 years
Trial Updated:
10/10/2023
Locations: TTU Kinesiology and Sport Management Building, Lubbock, Texas
Conditions: Type 2 Diabetes
Register for Updates
Effects of L-citrulline Supplementation on Vascular Function in Metabolic Syndrome
NCT06025357
Recruiting
The objective of this project is to provide evidence that L-Citrulline (CIT) supplementation can improve vascular function in the fasted and acute hyperglycemia conditions in middle-aged and older women with metabolic syndrome.
Gender:
FEMALE
Ages:
Between 45 years and 79 years
Trial Updated:
08/29/2023
Locations: TTU Kinesiology and Sport Management Building, Lubbock, Texas
Conditions: Metabolic Syndrome, Menopause
Register for Updates
2 Weeks of Citrulline Supplementation on Arterial Function in Postmenopausal Women With Elevated Blood Pressure or Hypertension
NCT06025383
Recruiting
The objective of this project is to elucidate the effect of L-Citrulline (L-CIT) supplementation on vascular function at rest and during rhythmic handgrip exercise and functional sympatholysis via lower-body negative pressure in postmenopausal women with elevated blood pressure and hypertension.
Gender:
FEMALE
Ages:
Between 50 years and 70 years
Trial Updated:
08/29/2023
Locations: Texas Tech University, Lubbock, Texas
Conditions: Menopause, Hypertension
Register for Updates